1 Report Scope
1.1 Scope of the Study 26
1.2 Precision Medicine: Report Coverage 27
1.3 Research Methodology 29
1.3.1 Research Methodology for the Global Market Study 30
1.3.1.1 Geographical Analysis 30
1.3.1.2 Demand Side & Supply Side Analysis 31
1.3.1.3 Data Synthesis and Bridging 31
1.3.2 Global Precision Medicine: Research Methodology 32
1.3.3 Key Data Point Sources 33
1.3.3.1 Data Points Taken from Secondary Sources 33
1.3.3.2 Data Points Taken from Primary Sources 33
1.4 Report Description 34
2 Executive Summary
3 Market Overview
3.1 Introduction 42
3.2 Market Timeline 42
3.3 Key Participants, Strategies & Developments 50
3.3.1 Government Agencies 50
3.3.2 Academic Institutions 50
3.3.3 Device & Service Providers 51
3.4 Key Market Strategies and Developments 51
3.4.1 Introduction 51
3.4.2 Partnerships, Agreements, and collaborations 52
3.4.3 Mergers & Acquisitions 54
3.4.4 Product Development and Launch 56
3.4.5 Business Expansion/Contracts 57
3.4.6 Patents, Approvals, and Certifications 59
3.4.7 Others (Events & Recognitions) 60
4 Market Dynamics
4.1 Introduction 61
4.2 Market Drivers 62
4.2.1 Patients Involvement in Personal Healthcare 62
4.2.2 Technologies Driving the Market (Next-Generation Sequencing Technologies, Ultra-High Throughput Sequencing)..64
4.2.3 Increase in Genetic Diseases 64
4.2.4 potential for More Targeted Therapies 65
4.2.5 Integration of Big Data Healthcare Companies with Pharma & Biotech Companies 65
4.3 Market Challenges 66
4.3.1 Potential Threat to Personal Data 66
4.3.2 High Diagnostic Cost as a Barrier 67
4.3.3 Potential Risk of Hardware or Software Failure 68
4.3.4 Stringent Regulations and Standards 68
4.3.5 Lack of Awareness about the Possible Applications of Precision Medicine 70
4.3.6 Reimbursement Policies and Regulatory Framework 71
4.3.7 Limited Knowledge About the Application of Test and Techniques 71
4.3.8 Lack of Research and Evidences Creating Hindrances in its Application 72
4.4 Market Opportunities 73
4.4.1 Introduction of Precision Medicine Solutions in Developing Economies 73
4.4.2 Downsizing the Cost of Genome Sequencing to Three Digits 74
5 Industry Dynamics
5.1 Value Chain Analysis 76
5.1.1 Device Manufacturer & Drug Producers 77
5.1.2 Healthcare Providers 77
5.1.3 Healthcare ITs or Big Data Companies 77
5.1.4 Regulators 77
5.1.5 Third Party Payers 78
5.1.6 Patients 78
5.2 Porter Five Force Analysis 78
5.2.1 Bargaining Power of Buyer (Patient) 79
5.2.2 Bargaining Power of Supplier 80
5.2.3 Threat from Substitute 82
5.2.4 Threat from a New Entrant 83
5.2.5 Intensity of Competitive Rivalry 84
6 Consortiums, Certification, Regulations, and Standards
6.1 Introduction 85
6.1.1 Regulatory Bodies 86
6.1.1.1 Food and Drug Administration (FDA) 89
6.1.1.2 Medicines and Healthcare products Regulatory Agency (MHRA) 91
6.1.1.3 Therapeutic Goods Administration (TGA)-Australia 91
6.1.1.4 Conformité Européenne (CE) 92
6.1.2 Consortiums 92
6.1.3 Alliances/Associations 94
7 Global Precision Medicine Market by Ecosystem Players
7.1 Introduction 96
7.1.1 Market Statistics 97
7.2 Pharmaceuticals and Biotechnology Companies 99
7.2.1 Key Market Trends, Developments, and Participants 105
7.2.1.1 Market Trends 105
7.2.1.2 Market Developments 105
7.2.1.3 Key Participants 106
7.3 Diagnostic Companies 107
7.3.1 Key Market Trends, Developments, and Participants 111
7.3.1.1 Market Trends 111
7.3.1.2 Market Developments 112
7.3.1.3 Key Participants 112
7.4 Healthcare it Specialists/Big Data Companies 113
7.4.1 Key Market Trends, Developments, and Participants 119
7.4.1.1 Market Trends 119
7.4.1.2 Market Developments 120
7.4.1.3 Key Participants 121
7.5 Clinical Laboratories 121
7.5.1 Key Market Trends, Developments, and Participants 125
7.5.1.1 Regulatory Bodies and Compliances 125
7.5.1.2 Market Trends 126
7.5.1.3 Key Participants 127
8 Global Precision Medicine Market by Sub-Markets
8.1 Introduction 128
8.1.1 Market Statistics 129
8.2 Companion Diagnostics 131
8.3 Biomarker-Based Test 135
8.3.1 Role of Biobanking into Biomarker 137
8.3.2 Key Participants 141
8.4 Targeted Therapeutics 142
8.4.1 Key Participants 144
8.5 Pharmacogenomics (PGX) 144
8.5.1 Key Market Trends, Developments, and Participants 149
8.5.1.1 Market Trends 149
8.5.1.2 Market Developments 150
8.5.1.3 Key Participants 151
8.6 Molecular Diagnostics 151
8.7 Others 157
8.7.1 Next-Generation Sequencing 159
8.7.2 Consumer Genomics 159
8.7.2.1 Key Participants 159
8.7.3 3D Printing 160
8.7.4 Prosthetics Market 160
8.7.5 Human Tissues Market 160
9 Global Precision Medicine Market by Therapeutics
9.1 Introduction 162
9.1.1 Market Statistics 163
9.2 Cancer/Oncology 164
9.2.1 Market Statistics 165
9.2.2 Types of Cancer 167
9.2.3 Drugs & Tests 170
9.2.4 Key Market Trends, Developments, and Participants 172
9.2.4.1 Market Trends 172
9.2.4.2 Market Developments 172
9.2.4.3 Key Participants 174
9.3 Cardiovascular Disease (CVD) 175
9.3.1 Market Statistics 176
9.3.2 Drugs & Tests 179
9.3.3 Market Trends and Market Developments 180
9.3.3.1 Market Trend 180
9.3.3.2 Market Developments 181
9.3.3.3 Key Participants 181
9.4 Central Nervous System 182
9.4.1 Market Statistics 182
9.4.2 Neurological 184
9.4.2.1 Neurological Drugs & Tests 185
9.4.3 Psychiatric Disorders 186
9.4.3.1 Psychiatric Disorder Drugs & Tests 186
9.4.4 Market Tends & Market Developments 188
9.4.4.1 Market Trends 188
9.4.4.2 Key Developments 188
9.4.4.3 Key Participants 188
9.5 Infectious Diseases 189
9.5.1 Market Statistics 189
9.5.2 Infectious Diseases Drugs & Tests 192
9.5.3 Market Developments & Participants 193
9.5.3.1 Key Developments 193
9.5.3.2 Key Participants 194
9.6 Others 194
9.6.1 Market Statistics 195
9.6.2 Market trends, Developments & Participants 200
9.6.2.1 Market Trends 200
9.6.2.2 Key Developments 200
9.6.2.3 Key Participants 201
10 Global Precision Medicine Market, by Geography
10.1 Introduction 202
10.1.1 Market Statistics 203
10.2 The Americas 204
10.2.1 North America 207
10.2.1.1 US. 208
10.2.1.2 Canada 209
10.2.1.3 Others 210
10.2.1.4 Key Market Trends, Developments, and Participants 210
10.2.1.5 Regulations and Compliances 210
10.2.1.6 Market Trends 210
10.2.1.7 Market Developments 211
10.2.1.8 Key Participants 211
10.2.2 South America 212
10.2.2.1 Key Market Trends, Developments, and Participants 212
10.2.2.2 Regulations and Compliances 212
10.2.2.3 Market Trends 212
10.2.2.4 Key Participants 212
10.3 Europe 213
10.3.1 Key Market Trends, Developments and Participants 216
10.3.1.1 Regulations and Compliances 216
10.3.1.2 Market Developments 216
10.3.1.3 Key Participants 218
10.4 Asia-Pacific (APAC) 218
10.4.1 Key Market Trends, Developments, and Participants 222
10.4.1.1 Market Developments 222
10.4.1.2 Key Participants 223
10.5 Rest of the World/Midde East & Africa (MEA) 223
10.5.1 Africa 225
10.5.1.1 Middle East 226
10.5.2 Key Market Developments and Participants 226
10.5.2.1 Market Developments 226
10.5.2.2 Key Participants 226
11 Company Profiles
11.1 Abbott Laboratories 227
11.1.1 Overview 227
11.1.2 Financials 228
11.1.2.1 Overall Financials 228
11.1.2.2 Financials by Segment 228
11.1.2.3 Financials by Region 229
11.1.2.4 Key Developments 229
11.1.3 SWOT Analysis 231
11.2 Almac Group, Ltd. 232
11.2.1 Overview 232
11.2.2 Financials 232
11.2.3 Key Developments 233
11.2.4 SWOT Analysis 234
11.3 Asuragen, Inc. 235
11.3.1 Overview 235
11.3.2 Financials 235
11.3.3 Key Developments 236
11.3.4 SWOT Analysis 237
11.4 BioMérieux SA 238
11.4.1 Overview 238
11.4.2 Financials 239
11.4.2.1 Overall Financials 239
11.4.2.2 Financials by Region 239
11.4.2.3 Financials by Segment 240
11.4.3 Key Developments 240
11.4.4 Swot Analysis 242
11.5 Cepheid Inc. 243
11.5.1 Overview 243
11.5.2 Financials 244
11.5.2.1 Overall Financials 244
11.5.2.2 Net Revenue by Segment 245
11.5.2.3 Net Revenue by Region 245
11.5.3 Key Developments 246
11.5.4 SWOT Analysis 247
11.6 CETICS Healthcare Technologies GmbH 248
11.6.1 Overview 248
11.6.2 Financials 248
11.6.3 Key Developments 249
11.6.4 SWOT Analysis 250
11.7 GE Healthcare 251
11.7.1 Overview 251
11.7.2 Financials 252
11.7.2.1 Overall Financials 252
11.7.2.2 Net Revenue by Segment 253
11.7.2.3 Financial Summary 254
11.7.3 Key Developments 254
11.8 Glaxosmithkline Plc (GSK) 256
11.8.1 Overview 256
11.8.2 Financials 257
11.8.2.1 Overall Financials 257
11.8.2.2 Financials by Segment 257
11.8.2.3 Financials by Region 258
11.8.2.4 Financials by Therapeutics 258
11.9 Intomics A/S 259
11.9.1 Overview 259
11.9.2 Financials 259
11.9.3 Key Developments 259
11.9.4 SWOT Analysis 260
11.10 Johnson & Johnson 261
11.10.1 Overview 261
11.10.2 Financials 262
11.10.2.1 Overall Financials 262
11.10.2.2 Net Revenue by Segment 262
11.10.2.3 Net revenue by Region 263
11.10.3 Key Developments 263
11.11 Laboratory Corporation of America Holdings 264
11.11.1 Overview 264
11.11.2 Financials 265
11.11.2.1 Overall Financials 265
11.11.2.2 Financials by Segment 266
11.11.3 Key Developments 266
11.11.4 SWOT Analysis 268
11.12 Medtronic 269
11.12.1 Overview 269
11.12.2 Financials 270
11.12.2.1 Overall Financials 270
11.12.3 Key Developments 270
11.13 Novartis 272
11.13.1 Overview 272
11.13.2 Financials 273
11.13.2.1 Overall Financials 273
11.13.2.2 Financials by Region 274
11.13.2.3 Financials by Segment 274
11.14 Pfizer Inc. 275
11.14.1 Overview 275
11.14.2 Financials 276
11.14.2.1 Overall Financials 276
11.14.2.2 Net Revenue by Segment 276
11.14.2.3 Net Revenue by Region 277
11.14.3 Key Developments 277
11.14.4 Swot Analysis 279
11.15 Qiagen 280
11.15.1 Overview 280
11.16 Biobase GmbH (Subsidiary) 281
11.16.1 Overview 281
11.16.2 Financials 282
11.16.2.1 Overall Financials 282
11.16.3 Key Developments (Biobase) 283
11.17 Quest Diagnostics Inc 284
11.17.1 Overview 284
11.17.2 Financials 285
11.17.2.1 Overall Financials 285
11.17.2.2 Net Revenue by Segment 286
11.17.3 Key Developments 286
11.17.4 SWOT Analysis 288
11.18 Randox Laboratories Ltd. 289
11.18.1 Overview 289
11.18.2 Financials 289
11.18.3 Key Developments 290
11.18.4 SWOT Analysis 291
11.19 Roche Holding AG-BR 292
11.19.1 Overview 292
11.19.2 Financials 293
11.19.2.1 Overall Financials 293
11.19.2.2 Net Revenue by Segment 293
11.19.3 Key Developments 294
11.19.4 SWOT Analysis 295
11.20 Sanofi Pharma 296
11.20.1 Overview 296
11.20.2 Financials 297
11.20.2.1 Overall Financials 297
11.20.2.2 Net Revenue by Segment 297
11.21 Takeda Pharmaceutical Company Limited 298
11.21.1 Overview 298
11.21.2 Financials 299
11.21.2.1 Overall Financials 299
11.21.3 Key Developments 299
11.21.4 SWOT Analysis 301
11.22 Teva Pharmaceutical Industries Ltd. 302
11.22.1 Overview 302
11.22.2 Financials 303
11.22.2.1 Overall Financials 303
11.22.2.2 Net Revenue by Segment 303
11.22.2.3 Net Revenue by Segment 304
11.22.3 Key Developments 304
11.22.4 SWOT Analysis 307
11.23 AB-Biotics SA 308
11.23.1 Overview 308
11.24 Caris Life Sciences 309
11.24.1 Overview 309
11.25 HealthCore, Inc. 310
11.25.1 Overview 310
11.26 IBM 311
11.26.1 Overview 311
11.27 InnVentis 312
11.27.1 Overview 312
11.28 Intel Corporation 313
11.28.1 Overview 313
11.29 Molecular Health GmbH 314
11.29.1 Overview 314
11.30 Precision for Medicine 315
11.30.1 Overview 315
12 List of Tables
TABLE 1 LEADING COMPANIES IN THE PRECISION MEDICINE MARKET 37
TABLE 2 DOWNSIZING COST OF GENOME SEQUENCING 74
TABLE 3 FACTORS IMPACTING THE BUYERS BARGAINING POWER 80
TABLE 4 FACTORS IMPACTING THE SUPPLIERS BARGAINING POWER 81
TABLE 5 FACTORS IMPACTING THE THREAT FROM SUBSTITUTE 82
TABLE 6 FACTORS IMPACTING THE THREAT FROM NEW ENTRANT 83
TABLE 7 FACTORS IMPACTING THE DEGREE OF COMPETITION 84
TABLE 8 REGULATORY BODIES IN PRECISION MEDICINE MARKET 87
TABLE 9 CONSORTIUMS IN PRECISION MEDICINE MARKET 93
TABLE 10 ALLIANCES/ASSOCIATIONSIN PRECISION MEDICINE MARKET 94
TABLE 11 GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2022-2030 (USD BILLION) 97
TABLE 12 PHARMA & BIOTECH: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES,
2022-2030 (USD BILLION) 100
TABLE 13 PHARMA & BIOTECH: GLOBAL PRECISION MEDICINE MARKET VALUE,
BY THERAPEUTIC APPLICATION, 2022-2030 (USD BILLION) 101
TABLE 14 PHARMA & BIOTECH: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY,
2022-2030 (USD BILLION) 102
TABLE 15 KEY DEVELOPMENTS IN PHARMA & BIOTECH COMPANIES (2020) 105
TABLE 16 DIAGNOSTIC TOOLS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES,
2022-2030 (USD BILLION) 107
TABLE 17 DIAGNOSTIC TOOLS: GLOBAL PRECISION MEDICINE MARKET VALUE,
BY THERAPEUTIC APPLICATION, 2022-2030 (USD BILLION) 108
TABLE 18 DIAGNOSTIC TOOLS: GLOBAL PRECISION MEDICINE MARKET VALUE,
BY GEOGRAPHY, 2022-2030 (USD BILLION) 109
TABLE 19 KEY DEVELOPMENTS IN DIAGNOSTIC COMPANIES(2020) 112
TABLE 20 HEALTHCARE ITS/BIG DATA: GLOBAL PRECISION MEDICINE MARKET VALUE,
BY SUB-MARKET TYPES, 2022-2030 (USD BILLION) 113
TABLE 21 HEALTHCARE ITS/BIG DATA: GLOBAL PRECISION MEDICINE MARKET VALUE,
BY THERAPEUTIC APPLICATION, 2022-2030 (USD BILLION) 114
TABLE 22 HEALTHCARE ITS/BIG DATA: GLOBAL PRECISION MEDICINE MARKET VALUE,
BY GEOGRAPHY, 2022-2030 (USD BILLION) 115
TABLE 23 KEY DEVELOPMENTS IN HEALTHCARE IT/BIG DATA COMPANIES(2020) 120
TABLE 24 CLINICAL LABORATORIES: GLOBAL PRECISION MEDICINE MARKET VALUE,
BY SUB-MARKET TYPES, 2022-2030 (USD BILLION) 122
TABLE 25 CLINICAL LABORATORIES: GLOBAL PRECISION MEDICINE MARKET VALUE,
BY THERAPEUTIC APPLICATION, 2022-2030 (USD BILLION) 123
TABLE 26 CLINICAL LABORATORIES: GLOBAL PRECISION MEDICINE MARKET VALUE,
BY GEOGRAPHY, 2022-2030 (USD BILLION) 124
TABLE 27 GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2022-2030 (USD BILLION) 129
TABLE 28 COMPANION DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE,
BY ECOSYSTEM PLAYERS, 2022-2030 (USD MILLION) 131
TABLE 29 COMPANION DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE,
BY THERAPEUTIC APPLICATION, 2022-2030 (USD MILLION) 132
TABLE 30 LIST OF APPROVED COMPANION DIAGNOSTIC DEVICES 133
TABLE 31 BIOMARKER: GLOBAL PRECISION MEDICINE MARKET VALUE,
BY ECOSYSTEM PLAYERS, 2022-2030 (USD MILLION) 135
TABLE 32 BIOMARKER: GLOBAL PRECISION MEDICINE MARKET VALUE,
BY THERAPEUTIC APPLICATION, 2022-2030 (USD MILLION) 136
TABLE 33 LIST OF BIOBANKS 138
TABLE 34 EXAMPLES OF BIOBANKING INITIATIVES ACROSS SELECTED OECD COUNTRIES 139
TABLE 35 TARGETED THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE,
BY ECOSYSTEM PLAYERS, 2022-2030 (USD MILLION) 142
TABLE 36 TARGETED THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE,
BY THERAPEUTIC APPLICATION, 2022-2030 (USD MILLION) 143
TABLE 37 PHARMACOGENOMICS: GLOBAL PRECISION MEDICINE MARKET VALUE,
BY ECOSYSTEM PLAYERS, 2022-2030 (USD MILLION) 145
TABLE 38 PHARMACOGENOMICS: GLOBAL PRECISION MEDICINE MARKET VALUE,
BY THERAPEUTIC APPLICATION, 2022-2030 (USD MILLION) 146
TABLE 39 MOLECULAR DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE,
BY ECOSYSTEM PLAYERS, 2022-2030 (USD MILLION) 152
TABLE 40 MOLECULAR DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE,
BY THERAPEUTIC APPLICATION, 2022-2030 (USD MILLION) 153
TABLE 41 OTHER SUB-MARKETS: GLOBAL PRECISION MEDICINE MARKET VALUE,
BY ECOSYSTEM PLAYERS, 2022-2030 (USD MILLION) 157
TABLE 42 OTHER SUB-MARKETS: GLOBAL PRECISION MEDICINE MARKET VALUE,
BY THERAPEUTIC APPLICATION, 2022-2030 (USD MILLION) 158
TABLE 43 GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS, 2022-2030 (USD BILLION) 163
TABLE 44 CANCER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS,
2022-2030 (USD BILLION) 165
TABLE 45 CANCER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2022-2030 (USD BILLION) 166
TABLE 46 CANCER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2022-2030 (USD BILLION) 167
TABLE 47 PRECISION MEDICINE DRUGS AND RELEVANT GENES: ONCOLOGY 170
TABLE 48 PRECISION MEDICINE GENETIC TESTS WITH RESPECT TO ONCOLOGY 171
TABLE 49 PRECISION MEDICINE MARKET KEY DEVELOPMENTS (2020–2020) 172
TABLE 50 CVD: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2022-2030 (USD BILLION) 176
TABLE 51 CVD: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2022-2030 (USD BILLION) 177
TABLE 52 CVD: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2022-2030 (USD MILLION) 178
TABLE 53 PRECISION MEDICINE DRUGS AND RELEVANT GENES: CARDIOVASCULAR 179
TABLE 54 PRECISION MEDICINE GENETIC TESTS WITH RESPECT TO CARDIOVASCULAR 180
TABLE 55 KEY DEVELOPMENTS (2020–2020) 181
TABLE 56 CNS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2022-2030 (USD MILLION) 182
TABLE 57 CNS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2022-2030 (USD MILLION) 183
TABLE 58 CNS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2022-2030 (USD MILLION) 184
TABLE 59 PRECISION MEDICINE DRUGS AND RELEVANT GENES: NEUROLOGY 185
TABLE 60 PRECISION MEDICINE DRUGS AND RELEVANTGENES: PSYCHIATRIC DISORDERS 186
TABLE 61 PRECISION MEDICINE GENETIC TESTS WITH RESPECT TO PSYCHIATRIC DISORDERS 187
TABLE 62 PSYCHIATRIC DISORDERS: PRECISION MEDICINE MARKET KEY DEVELOPMENTS (2020–2020) 188
TABLE 63 INFECTIOUS DISEASE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS,
2022-2030 (USD MILLION) 189
TABLE 64 INFECTIOUS DISEASE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES,
2022-2030 (USD MILLION) 190
TABLE 65 INFECTIOUS DISEASE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY,
2022-2030 (USD MILLION) 191
TABLE 66 PRECISION MEDICINE DRUGS AND RELEVANT GENES: INFECTIOUS DISEASES 192
TABLE 67 OTHER THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS,
2022-2030 (USD MILLION) 195
TABLE 68 OTHER THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES,
2022-2030 (USD MILLION) 196
TABLE 69 OTHER THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY,
2022-2030 (USD MILLION) 197
TABLE 70 PRECISION MEDICINE DRUGS AND RELEVANT GENES: OTHER DISEASES 198
TABLE 71 PRECISION MEDICINE GENETIC TESTS WITH RESPECT TO OTHER DISEASES 199
TABLE 72 GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2022-2030 (USD BILLION) 203
TABLE 73 AMERICAS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS,
2022-2030 (USD BILLION) 204
TABLE 74 AMERICAS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS,
2022-2030 (USD BILLION) 205
TABLE 75 AMERICAS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS,
2022-2030 (USD BILLION) 206
TABLE 76 EUROPE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS,
2022-2030 (USD BILLION) 213
TABLE 77 EUROPE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS,
2022-2030 (USD BILLION) 214
TABLE 78 APAC: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2022-2030 (USD BILLION) 219
TABLE 79 APAC: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS,
2022-2030 (USD MILLION) 220
TABLE 80 ROW: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2022-2030 (USD MILLION) 224
TABLE 81 ROW: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS,
2022-2030 (USD MILLION) 225
13 List of Figures
FIGURE 1 PRECISION MEDICINE MARKET STUDY 27
FIGURE 2 PRECISION MEDICINE MARKET RESEARCH METHODOLOGY 29
FIGURE 3 DIFFERENT PHASES OF RESEARCH METHODOLOGY FOR THE GLOBAL PRECISION MEDICINE MARKET 30
FIGURE 4 PRECISION MEDICINE MARKET: RESEARCH METHODOLOGY 32
FIGURE 5 GLOBAL PRECISION MEDICINE MARKET SHARE, BY ECOSYSTEM, 2022-2030 (USD BILLION) 38
FIGURE 6 GLOBAL PRECISION MEDICINE MARKET SIZE, BY SUB-MARKET TYPE, 2022-2030 (BILLION) 39
FIGURE 7 GLOBAL PRECISION MEDICINE MARKET SIZE, BY THERPEUTIC APPLICATION, 2022-2030 (BILLION) 40
FIGURE 8 GLOBAL PRECISION MEDICINE MARKET SIZE, BY GEOGRAPHY, 2020 – 2027 (USD BILLION) 41
FIGURE 9 TIMELINE OF PRECISION MEDICINE 43
FIGURE 10 PRECISION MEDICINE MARKET: BENEFITS 45
FIGURE 11 EXAMPLES: APPLIED AREAS OF PRECISION MEDICINE 46
FIGURE 12 ELEMENTS OF PRECISION MEDICINE MARKET TECHNOLOGY 47
FIGURE 13 PRECISION MEDICINE MARKET : DIFFERENT TYPE OF DATA USED BY BIG DATA COMPANIES 48
FIGURE 14 PRECISION MEDICINE MARKET : AREAS OF INTEREST 49
FIGURE 15 PRECISION MEDICINE MARKET : PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS (2020) 53
FIGURE 16 PRECISION MEDICINE MARKET : MERGERS & ACQUISITIONS (2020) 55
FIGURE 17 PRECISION MEDICINE MARKET : KEY PRODUCT LAUNCH & DEVELOPMENTS (2020) 57
FIGURE 18 PRECISION MEDICINE MARKET : KEY BUSINESS EXPANSIONS & CONTRACTS (2020) 58
FIGURE 19 PRECISION MEDICINE MARKET : KEY PATENTS/ APPROVALS (2020) 59
FIGURE 20 PRECISION MEDICINE MARKET: EVENTS & RECOGNITION (2020) 60
FIGURE 21 PRECISION MEDICINE MARKET DRIVERS AND CHALLENGES 61
FIGURE 22 BENEFITS OF PRECISION MEDICINE TO PATIENTS 63
FIGURE 23 MAJOR BARRIERS CAUSED BY REGULATION AND STANDARDS 69
FIGURE 24 FLOW CHART OF PRECISION MEDICINE MARKET 76
FIGURE 25 PRECISION MEDICINE MARKET : PORTER FIVE FORCE ANALYSIS 79
FIGURE 26 ROLES AND RESPONSIBILITIES OF HEALTHCARE POLICY MAKERS 86
FIGURE 27 ROLE OF FDA IN PRECISION MEDICINE 90
FIGURE 28 CLASSIFICATION OF MEDICAL DEVICES 91
FIGURE 29 GLOBAL PRECISION MEDICINE MARKET BY ECOSYSTEM PLAYERS 98
FIGURE 30 ROLE OF PHARMACEUTICALS AND BIOTECH COMPANIES 103
FIGURE 31 PRECISION MEDICINE MARKET CHALLENGES FACED BY PHARMA & BIOTECH COMPANIES 104
FIGURE 32 DIAGNOSTIC TESTS BENEFITS FOR STAKEHOLDERS 110
FIGURE 33 CHALLENGES FACED BY DIAGNOSTIC COMPANIES 111
FIGURE 34 BENEFITS OF BIG DATA 116
FIGURE 35 TRANSFORMATION OF MEDICINE 117
FIGURE 36 BASIC INGREDIENTS PROVIDED BY BIG DATA FOR PRECISION MEDICINE 118
FIGURE 37 PRECISION MEDICINE MARKET CHALLENGES FACED BY BIG DATA COMPANIES 119
